TrialThe Lancet. Infectious diseases2021

Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study.

Paul A Goepfert et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.